Cookson Peirce & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Cookson Peirce & Co’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-71,163	Closed	-$1.7M	–	204
2023 Q2	$1.7M	Buy	+71,163	New	+$1.58M	0.1%	82
2020 Q3	–	Sell	-14,997	Closed	-$727K	–	139
2020 Q2	$727K	Buy	14,997 +7,772	+108%	+$373K	0.07%	86
2020 Q1	$305K	Buy	+7,225	New	+$298K	0.04%	111

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Cookson Peirce & Co's ACAD Position: Q3 2023 in Review

Cookson Peirce & Co sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 71,163 shares — an estimated $1.7M sold.

Cookson Peirce & Co first reported a position in ACAD in Q1 2020 and held it in 3 quarters. The position peaked at $1.7M in Q2 2023. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

Cookson Peirce & Co reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Cookson Peirce & Co sold 71,163 Acadia Pharmaceuticals shares in Q3 2023, an estimated $1.7M.
Cookson Peirce & Co first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 3 quarters.
Cookson Peirce & Co's Acadia Pharmaceuticals position peaked at $1.7M in Q2 2023.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Cookson Peirce & Co's 13F filing for Q3 2023, filed 7 Nov 2023.